Trafalgar International (GCAN) Shares Outstanding (2016 - 2026)
Trafalgar International (GCAN) posted Shares Outstanding (Entity) of $944935.0 for Q1 2026, little changed on a QoQ basis from $944935.0 in Q4 2025, and down 99.9% year-over-year from $974.9 million in Q1 2025.
Analysis
Trafalgar International (GCAN) Shares Outstanding (2016 - 2026) Analysis & Trends
Trafalgar International has reported Shares Outstanding (Entity) for 11 years, with the latest figure at $944935.0 in Q1 2026.
- On a quarterly basis, Shares Outstanding (Entity) fell 99.9% year-over-year to $944935.0 in Q1 2026; TTM through Mar 2026 was $944935.0, a 99.9% decrease from a year earlier, with the FY2025 full-year figure at $944935.0, down 99.88% from the prior year.
- Shares Outstanding (Entity) was $944935.0 for Q1 2026 at Trafalgar International, roughly flat from $944935.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.3 billion in Q2 2025, with the low at $900256.0 in Q3 2025.
- Average Shares Outstanding (Entity) over 5 years is $640.2 million, with a median of $732.6 million recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) soared 67.76% in 2025, then slumped 99.9% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $587.8 million in 2022, then soared by 36.9% to $804.6 million in 2023, then changed by 0.0% to $804.6 million in 2024, then plunged by 99.88% to $944935.0 in 2025, then changed by 0.0% to $944935.0 in 2026.
- The last three Shares Outstanding (Entity) figures came in at $944935.0 (Q1 2026), $944935.0 (Q4 2025), and $900256.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 1.94 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 5.70 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 210.89 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 200.38 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 42.60 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | 944,935.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 944,935.00 |
| Dec 31, 2025 | 824,984.00 |
| Sep 30, 2025 | 900,256.00 |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | 910.37 Mn |
| Dec 31, 2024 | 804.64 Mn |
| Sep 30, 2024 | 804.64 Mn |
| Jun 30, 2024 | 804.64 Mn |
| Mar 31, 2024 | 732.64 Mn |
| Dec 31, 2023 | 755.15 Mn |
| Sep 30, 2023 | 766.68 Mn |
| Jun 30, 2023 | 732.64 Mn |
| Mar 31, 2023 | 732.64 Mn |
| Dec 31, 2022 | 587.77 Mn |
| Sep 30, 2022 | 617.92 Mn |
| Jun 30, 2022 | 516.97 Mn |
| Mar 31, 2022 | 508.64 Mn |
| Dec 31, 2021 | 489.50 Mn |
| Sep 30, 2021 | 492.98 Mn |
| Jun 30, 2021 | 478.64 Mn |